Research & Development: Page 10
-
Scott Olson via Getty Images
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.
By Jonathan Gardner • Oct. 15, 2024 -
Getty Images
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s
The Alzheimer’s space is booming, from a new use for a schizophrenia drug to discovered pathways linked to the disease — but there’s been stumbles too.
By Meagan Parrish • Oct. 11, 2024 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
Getty Images
Regeneron takes the long-haul approach to oncology, stumbles and all
Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.
By Michael Gibney • Oct. 10, 2024 -
Getty Images
As AI transforms drug development, biotechs might not need as much Big Pharma support
Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.
By Amy Baxter • Oct. 9, 2024 -
Scott Olson via Getty Images
Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds
Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.
By Kelly Bilodeau • Oct. 7, 2024 -
Getty Images
An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped?
Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.
By Meagan Parrish • Oct. 4, 2024 -
iStock via Getty Images
How Roche plans to fill a projected $8B sales gap
Biosimilar competition will erode billions from the pharma giant’s top line in the next few years.
By Amy Baxter • Oct. 2, 2024 -
Getty Images
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.”
By Gwendolyn Wu • Oct. 2, 2024 -
Permission granted by Biocom
Q&ACalifornia is a life sciences leader. Joe Panetta has been one of its most vocal advocates.
The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.
By Alexandra Pecci • Oct. 1, 2024 -
Getty Images
After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum?
The company’s allogeneic therapy was OK’d in the EU and could become the first of its kind approved by the FDA in January — while eyeing the next frontier.
By Kelly Bilodeau • Sept. 30, 2024 -
Getty Images
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.
By Kelly Bilodeau • Sept. 26, 2024 -
Permission granted by Roivant Sciences
Q&ARoivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters
Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.
By Michael Gibney • Sept. 26, 2024 -
Getty Images
Fresh data intensifies race for a major gene therapy target
4D Molecular Therapeutics reported positive interim analysis in the high-potential wet AMD indication last week.
By Meagan Parrish • Sept. 25, 2024 -
Permission granted by CRI
Q&A // First 90 DaysWant better cancer treatments? Make biopharma more like Silicon Valley
Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.
By Michael Gibney • Sept. 24, 2024 -
Permission granted by Ovid Therapeutics
After epilepsy setback, Ovid charges confidently ahead in CNS
A promising epilepsy drug Ovid sold to Takeda recently missed the mark in late-stage trials. But Ovid believes it has other novel mechanisms that could deliver a CNS win.
By Meagan Parrish • Sept. 20, 2024 -
Getty Images
At J&J, oncology R&D meets commercial strategy in a quest for new standards of care
The disparate teams of research and commercial at J&J work closely together from the get-go.
By Michael Gibney • Sept. 19, 2024 -
Sarah Silbiger via Getty Images
Getting IND ready — how companies can avoid common traps
Overpromising, overcommitting and neglecting CMC are a few of the pitfalls that cause sponsors to stumble when submitting a new drug application.
By Alexandra Pecci • Sept. 18, 2024 -
Getty Images
How a radiopharma up-and-comer builds momentum in a surging space
Big Pharma is embracing the radiopharmaceuticals boom that was a long time in the making.
By Michael Gibney • Sept. 17, 2024 -
Getty Images
The hunt for game-changers against the deadliest form of brain cancer
Treatments for glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts.
By Kelly Bilodeau • Sept. 16, 2024 -
Getty Images
Who’s winning in biotech’s tight market?
Three of the largest fundraising rounds in 2024 show where investors are willing to place their bets in biotech.
By Meagan Parrish • Sept. 13, 2024 -
Permission granted by Sanofi
3 FDA approval dates to watch in the year’s final push
A handful of potential blockbusters are marching toward FDA review.
By Amy Baxter • Sept. 11, 2024 -
Permission granted by Organon
Why pharma should redefine ‘women’s health’
A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon.
By Alexandra Pecci • Sept. 11, 2024 -
George Frey/Reuters
Deep DiveA decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
By Jonathan Gardner • Sept. 10, 2024 -
Getty Images
Huntington’s disease R&D is regaining ground after several disappointments
Setbacks haven’t stopped advances by biotechs and pharmas working on new drugs for the inherited brain disorder.
By Kelly Bilodeau • Sept. 9, 2024 -
Scott Olson via Getty Images
Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies
The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.
By Amy Baxter • Sept. 9, 2024
Previous
